The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients
Abstract
Aim To compare the efficacy and safety of premixed insulin aspart (30% free and 70% protamine‐bound, BIAsp 30) with human insulin premix (BHI 30) used in a twice‐daily injection regimen in people with Type 1 and Type 2 diabetes. Methods People with Type 1 and Type 2 diabetes (n = 294) using twice‐daily insulin were randomized to a 12‐week open‐label comparison of BIAsp 30 and BHI 30. Efficacy was assessed by analysis of variance of 12‐week data, adjusted for baseline level. Results BIAsp 30 was as effective as BHI 30 based on the primary efficacy measure, HbA 1c, mean difference –0.01 (90% confidence interval (CI) –0.14; 0.12) %Hb. Meal‐time self‐measured blood glucose increment averaged over the three main meals was significantly lower in the BIAsp 30 group than in the BHI 30 group (–0.68 (–1.20; –0.16) mmol/l; P < 0.02). Significant improvements were observed after breakfast, before lunch, after dinner and at bedtime (P < 0.02–0.05), with blood glucose around 1.0 mmol/l lower in the BIAsp 30 group. The number of major hypoglycaemic episodes with BIAsp 30 was half that with BHI 30. However, the overall risk of both minor and major hypoglycaemia did not differ significantly between treatments. Conclusion Post‐prandial glycaemic control was significantly improved, without increasing the risk of hypoglycaemia, and overall control was similar when people with Type 1 and Type 2 diabetes were treated on a twice‐daily regimen with immediate premeal injections of BIAsp 30 compared with BHI 30. Diabet. Med. 19, 393–399 (2002)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324
Cited by
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A., Plank, J., Berghold, A., Jeitler, K., Horvath, K., Narath, M., Gfrerer, R., & Pieber, T. R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub4 · Cited by 264
Home, P. D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01580.x · Cited by 212
Self-citationPharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
Mannucci, E., Monami, M., & Marchionni, N. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00934.x · Cited by 96
Metadata
- Authors
- Boehm, B. O., Home, P. D., Behrend, C., Kamp, N. M., & Lindholm, A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2002-05
- Volume
- 19
- Issue
- 5
- Pages
- 393-399
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1512877138
- Cited by
- 176
- References
- 2
- FWCI
- 6.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. https://app.cochat.ai/papers/10.1046/j.1464-5491.2002.00733.x
- The paper
- Boehm, B. O., Home, P. D., Behrend, C., Kamp, N. M., & Lindholm, A. (2002). Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2002.00733.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.